Learning Implementation of Guideline-based Decision Support System for Hypertension Treatment: Testing Alternative Antihypertensive Regimens Using ACE-Inhibitors, Calcium Channel Blockers and Diuretics (LIGHT-ACD)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hypertension
- Sponsor
- China National Center for Cardiovascular Diseases
- Enrollment
- 5000
- Locations
- 3
- Primary Endpoint
- Average change in BP from first visit after the decision support system is installed to 9-month among the individuals who initiated with A, C, and D (population 1) and among those who initiated with two-drug therapy with AC, AD or CD (population 2)
- Last Updated
- 5 years ago
Overview
Brief Summary
This trial aims to compare the efficacy of several guideline-based hypertensive medication regimens initiated with Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker [A], Calcium Channel Blocker [C] and Diuretic [D].
Detailed Description
The LIGHT-ACD Trial is conducted based on the LIGHT trial and aims to compare the efficacy of several guideline-based hypertensive medication regimens initiated with A, C and D for BP control.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Average change in BP from first visit after the decision support system is installed to 9-month among the individuals who initiated with A, C, and D (population 1) and among those who initiated with two-drug therapy with AC, AD or CD (population 2)
Time Frame: Baseline; 1 year
Average change in BP from first visit after the decision support system is installed to 9-month among population 1 (SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D and among population 2 (SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD, respectively.
Secondary Outcomes
- Proportion of individuals intolerant to each of the four medications.(Baseline; 1 year)
- Proportion of individuals with BP<160/100 mmHg at 9 month.(Baseline; 1 year)
- Proportion of individuals with BP<140/90 mmHg at 9 month.(Baseline; 1 year)
- Proportion of individuals who received monotherapy, two-drug treatment, three-drug treatment, or referral at 9 month.(Baseline; 1 year)
- Proportion of individuals who switched to usual care for any reason.(Baseline; 1 year)